Wall Street analysts forecast that Crispr Therapeutics AG (NASDAQ:CRSP) will post $3.96 million in sales for the current fiscal quarter, Zacks reports. Four analysts have made estimates for Crispr Therapeutics' earnings. The lowest sales estimate is $250,000.00 and the highest is $14.80 million. Crispr Therapeutics reported sales of $211.93 million during the same quarter last year, which would suggest a negative year-over-year growth rate of 98.1%. The company is expected to report its next quarterly earnings report on Monday, October 26th.
According to Zacks, analysts expect that Crispr Therapeutics will report full year sales of $7.19 million for the current year, with estimates ranging from $200,000.00 to $29.90 million. For the next fiscal year, analysts forecast that the business will post sales of $38.67 million, with estimates ranging from $3.50 million to $90.00 million. Zacks Investment Research's sales averages are an average based on a survey of research analysts that cover Crispr Therapeutics.
Crispr Therapeutics (NASDAQ:CRSP) last posted its earnings results on Monday, July 27th. The company reported ($1.30) EPS for the quarter, missing analysts' consensus estimates of ($0.95) by ($0.35). Crispr Therapeutics had a return on equity of 2.35% and a net margin of 6.77%. The company had revenue of $0.04 million during the quarter, compared to the consensus estimate of $19.77 million. During the same period last year, the firm posted ($1.01) EPS. The company's revenue for the quarter was down 86.2% on a year-over-year basis.
Several research firms have issued reports on CRSP. Barclays increased their price objective on shares of Crispr Therapeutics from $65.00 to $102.00 and gave the company an "overweight" rating in a report on Tuesday, July 28th. Chardan Capital raised their price objective on shares of Crispr Therapeutics from $72.50 to $100.00 and gave the stock a "buy" rating in a research report on Tuesday, July 28th. SunTrust Banks assumed coverage on shares of Crispr Therapeutics in a research report on Tuesday, July 14th. They set a "buy" rating and a $140.00 price target for the company. Piper Sandler reiterated an "overweight" rating and set a $104.00 price target on shares of Crispr Therapeutics in a research report on Friday, June 19th. Finally, Roth Capital lifted their price target on shares of Crispr Therapeutics from $100.00 to $105.00 and gave the company a "buy" rating in a research report on Friday, June 19th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and twelve have given a buy rating to the stock. Crispr Therapeutics has a consensus rating of "Buy" and an average target price of $90.93.
In other Crispr Therapeutics news, VP Tony W. Ho sold 7,158 shares of the firm's stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $75.04, for a total transaction of $537,136.32. Following the completion of the sale, the vice president now directly owns 40,676 shares in the company, valued at approximately $3,052,327.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, President Rodger Novak sold 50,000 shares of the firm's stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $75.00, for a total value of $3,750,000.00. Following the sale, the president now owns 698,007 shares of the company's stock, valued at $52,350,525. The disclosure for this sale can be found here. Insiders sold a total of 187,246 shares of company stock worth $14,605,668 in the last three months. 17.10% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Morgan Stanley raised its stake in shares of Crispr Therapeutics by 233.6% in the 1st quarter. Morgan Stanley now owns 851,519 shares of the company's stock valued at $36,113,000 after acquiring an additional 596,255 shares in the last quarter. Wells Fargo & Company MN raised its stake in shares of Crispr Therapeutics by 23.1% in the 1st quarter. Wells Fargo & Company MN now owns 501,519 shares of the company's stock valued at $21,270,000 after acquiring an additional 94,137 shares in the last quarter. Public Employees Retirement Association of Colorado bought a new position in shares of Crispr Therapeutics in the 2nd quarter valued at approximately $508,000. Swiss National Bank raised its stake in shares of Crispr Therapeutics by 51.5% in the 2nd quarter. Swiss National Bank now owns 88,300 shares of the company's stock valued at $6,489,000 after acquiring an additional 30,000 shares in the last quarter. Finally, Invesco Ltd. raised its stake in shares of Crispr Therapeutics by 42.7% in the 1st quarter. Invesco Ltd. now owns 190,307 shares of the company's stock valued at $8,071,000 after acquiring an additional 56,928 shares in the last quarter. Hedge funds and other institutional investors own 55.29% of the company's stock.
Shares of NASDAQ CRSP opened at $93.93 on Thursday. The company's fifty day moving average price is $90.64 and its 200 day moving average price is $65.33. Crispr Therapeutics has a 1 year low of $32.30 and a 1 year high of $105.12. The company has a market capitalization of $6.59 billion, a PE ratio of 204.20 and a beta of 2.29.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Story: How to Profit and Limit Losses With Stop Orders
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]